FDA warns of rare skin reaction from Celgene's Revlimid

09/19/2008 | Wall Street Journal, The

Celgene's Revlimid, a treatment for blood cancer, may have caused 14 cases of Stevens-Johnson syndrome, a rare but serious skin reaction also known as toxic epidermal necrolysis, the FDA said on its Web site. The finding is based on the agency's postmarketing safety review of Revlimid, which was approved in December 2005.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX